BIOLOGICAL BASIS FOR THE USE OF CARDIOMETABOLIC DRUGS IN ATHLETES
Maladaptive remodeling, the formation of «pathological cardiac hypertrophy» athlete, changes in the central hemodynamics and a possible continuum of chronic heart failure in the athlete are the leading problems of modern sports cardiology. According to the literature, in many cases, the treatment of maladaptive athlete cardiomyopathy, which is an independent risk for sudden cardiac death in an athlete, usually limited to a change in training mode, and their complete abolition or the appointment of symptomatic therapy: treatment of hypertension, heart failure, electrolyte disturbances and repolyarizatsionnyh. In recent decades, a success for the prevention and treatment of «stress» sportsmen cardiomyopathy metabolic therapy used.